Fatty acid amide hydrolase (FAAH) is an intracellular enzyme catalyzing hydrolysis of endogenous lipid mediators, such as anandamide, an endogenous cannabinoid , oleoyethanolamide (OEA) and palmitoyethanolamide (PEA). OEA and PEA are structurally similar to anandamide, but do not bind to or activate cannabinoid CB1 receptors and, instead, bind to and activate the nuclear peroxisome proliferator-activated receptor-alpha (PPAR–α), as does anandamide. PPAR–α is a ligand-activated receptor that regulates expression of genes involved in lipid utilization, fatty acid oxidation and inflammation. Drugs that inhibit FAAH increase anandamide, OEA and PEA levels in the brain, which could have clinically significant anti-inflammatory, neuroprotective and cognition-altering effects. URB597 is a selective FAAH inhibitor now entering clinical trial for analgesia. We studied URB597 effects on learning and memory in Sprague-Dawley rats with a step-through passive-avoidance task. During a single learning trial, rats were placed in the light compartment of a shuttle-box and received footshock upon entering the dark compartment. When URB597 (0.1–1.0mg/kg) was given before the learning trial, latencies to enter the dark compartment during a retention test one day later significantly increased. When the PPAR–α agonist WY14643 (40mg/kg) and the cannabinoid CB1 antagonist rimonabant (SR141716A, 3.0mg/kg) were given before the learning trial, they produced similar increases in latencies to enter the dark compartment during the retention test. In contrast, latencies to enter the dark compartment were markedly decreased by the CB1-receptor agonist Δ-tetrahydrocannabinol (THC; 3.0–5.6mg/kg). The effects of URB597 and WY14643 were blocked by the PPAR–α antagonist MK886 (1.0mg/kg). These results suggest a strong involvement of PPAR–α receptors in mnemonic processes. PPAR–α receptors are present in large numbers in brain areas involved in learning and memory, such as the hippocampus and amygdala, and are involved in regulation of acetylcholine biosynthesis and inflammatory processes that may contribute to cognitive decline with ageing and Ahlzheimer's disease. The present findings provide a novel mechanism for cognitive enhancement by FAAH inhibition and suggest a new approach to development of medications to combat cognitive decline associated with ageing and Ahlzheimer's disease.